Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L)

Peer Review reports

Original Submission
4 Feb 2023	Submitted	Original manuscript
Resubmission - Version 2
	Submitted	Manuscript version 2
Resubmission - Version 3
	Submitted	Manuscript version 3
30 May 2023	Reviewed	Reviewer Report
12 Jun 2023	Reviewed	Reviewer Report
30 Jun 2023	Author responded	Author comments - Kazushige Wakuda
Resubmission - Version 4
30 Jun 2023	Submitted	Manuscript version 4
2 Jul 2023	Author responded	Author comments - Kazushige Wakuda
Resubmission - Version 5
2 Jul 2023	Submitted	Manuscript version 5
10 Jul 2023	Reviewed	Reviewer Report
20 Aug 2023	Reviewed	Reviewer Report
29 Aug 2023	Author responded	Author comments - Kazushige Wakuda
Resubmission - Version 6
29 Aug 2023	Submitted	Manuscript version 6
17 Sep 2023	Reviewed	Reviewer Report
Resubmission - Version 7
	Submitted	Manuscript version 7
Publishing
18 Sep 2023	Editorially accepted
25 Sep 2023	Article published	10.1186/s12885-023-11417-w

Back to article page